Abstract
Temozolomide, a novel triazene derivative, has shown activity in vitro against lung cancer as well as against brain metastases from a variety of solid tumors including non-small cell lung cancer (NSCLC). The aim of the study was to evaluate the efficacy and safety of temozolomide in pretreated patients with NSCLC. Thirty-one pretreated patients (median age 60 years) with histologically confirmed NSCLC were enrolled. Sixteen (52%) patients had a performance status (ECOG) of 0-1, 12 (39%) had pretreated brain metastases and 28 (90.3%) had received >2 lines of treatment. Temozolomide was administered at a dose of 75 mg/m(2) daily for 21 days every 28 days. A total of 73 chemotherapy cycles were administered. In an intention-to-treat analysis, 2 patients (6.5%; 95% CI: -2.2 to 15.1%) achieved a partial response and 3 (10%) stable disease. The median time to progression was 2.4 months, the median survival time 3.3 months and the 1-year survival rate 22.5%. There was a toxic death due to grade 4 neutropenia. Grade 3 and 4 lymphopenia occurred in 4 (13%) and 2 (6%) patients, respectively. Nonhematological toxicity was mild, consisting of grade 2-3 asthenia (n = 14 patients) and grade 3 diarrhea (n = 1 patient). Prolonged low daily dos...Continue Reading
Citations
Mar 11, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ryuya YamanakaTetsushi Fukushige
Jul 28, 2009·Apoptosis : an International Journal on Programmed Cell Death·Angeliki KoryllouVassiliki Pletsa
May 2, 2009·Pharmaceutical Research·Mei Lan TanTengku Sifzizul Tengku Muhammad
Dec 1, 2010·Pharmaceutical Research·Nathalie WauthozKarim Amighi
Aug 28, 2013·Indian Journal of Cancer·V NoronhaK Prabhash
Mar 12, 2013·Cancer Chemotherapy and Pharmacology·Adriana RomitiPaolo Marchetti
Aug 3, 2013·Wiener klinische Wochenschrift·Marco Ronald HasslerChristine Marosi
May 14, 2009·Expert Opinion on Drug Safety·Van Anh TrinhWen-Jen Hwu
Jul 24, 2015·International Journal of Oncology·Rémi RosièreNathalie Wauthoz
Jul 24, 2012·Cancer Treatment Reviews·Zuzana TatarXavier Durando
Jan 30, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Nathalie WauthozKarim Amighi
Jan 20, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Carlos Gamboa-VignolleAlejandro Mohar
Jul 29, 2016·PloS One·Olga PapadodimaVasiliki Pletsa
Feb 13, 2018·Oncology Letters·Bing LiMinhui Xu
May 20, 2020·Frontiers in Oncology·Sushma JonnaStephen V Liu
Apr 25, 2019·Journal of Oncology·Cem SimsekSuayib Yalcin
Dec 1, 2020·Critical Reviews in Oncology/hematology·Palma FedeleSaverio Cinieri
Dec 30, 2020·Medicine·Yi YangMingfang Xu
Jun 3, 2021·Cancers·Marina Elena CazzanigaMaria Grazia Cerrito